Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

10 Episodes
Subscribe

By: Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at http://HCPLive.com/Clinical/Endocrinology. Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com. Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.

2024 ACP Type 2 Diabetes Recommendations
04/20/2024

The American College of Physicians has released new recommendations in favor of SGLT2i and GLP-1 RA and against the use of DPP-4i as second-line therapies to metformin in adults with type 2 diabetes and inadequate glycemic control. Released on the first day of the ACP’s Internal Medicine Meeting 2024, the pair of recommendations reflect the findings from a systematic review and network meta-analysis and cost-effectiveness analysis assessing the value of these therapies as both monotherapies and in combination with metformin.

Attendees at this year’s meeting, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the ACP’s late...


STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies
04/20/2024

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, tackle a pair of related topics: what the STEP HFpEF DM trial from ACC.24 means for the diabetes community and the need for fair and equitable allocation of incretin-based therapies in the face of ongoing drug shortages and overwhelming demand.


What to Know about Sequel Med Tech's twiist AID System, with Alan Lotvin, MD
03/30/2024

The diabetes community welcomed an additional tool to the armamentarium with the US Food and Drug Administration’s clearance of the twiist automated insulin delivery (AID) system on March 18, 2024. Cleared for use in patients aged 6 years and older with type 1 diabetes, the twiist, which is marketed by Sequel Med Tech, is billed as the first drug delivery system that directly measures volume and flow of inulin delivered with every micro-dose.

In this episode, Alan Lotvin, MD, co-founder and CEO of Sequel Med Tech, offers hosts a deep dive into the latest AID to receive approval, including the pump’s pa...


Hot Topics and Updates from ATTD 2024
03/30/2024

In the third and final recap episode from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes, hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into a series of topics from the meeting, including GLP-1 receptor agonist use and CGM technology, updates in once-weekly insulins, the concept of continuous ketone monitoring, and application of artificial intelligence into care.

Video version: https://www.hcplive.com/view/diabetes-dialogue-hot-topics-and-updates-from-attd-2024 


T1D Glycemic Improvement and CRISTAL at ATTD 2024
03/26/2024

In this episode, hosts provide insight from automated insulin delivery updates from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes. The specific topics of note covered in this study include new data related to diabetes technology use from the Type 1 Diabetes (T1D) Exchange and a read-out of data from the CRISTAL trial.


FLOW Trial and Chronic Kidney Disease Updates, with Brendon Neuen, MBBS, PhD
03/22/2024

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives hosts are joined by Brendon Neuen, MBBS, PhD, nephrologist and director of the Kidney Trials Unit at Royal North Shore Hospital and senior research fellow at The George Institute for Global Health.

During the episode, Neuen talks about the FLOW trial, topline results, how the rapid advancement in pharmacotherapies has altered conversations around management, the concept of 4 pillars of GDMT for CKD in type 2 diabetes, and how to approach sequencing of these therapies.

Video Version: https://www.hcplive.com/view/diabetes-dialogue-flow-trial-and-chronic-kidney-disease-updates-with-brendon-neuen-mbbs-phd

Episode Highlights
<...


Dexcom Stelo and CGM Updates, with Jake Leach
03/22/2024

Hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives recorded a special edition episode with Jake Leach, chief operating officer of Dexcom. The episode itself represents a follow-up to a conversation a year ago at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2023, where Leach discussed the ongoing global rollout of the Dexcom G7 and how he expected expanded coverage of the device to open doors to greater personalization of care for people with diabetes.

In the current episode, Leach and hosts touch upon the Stelo clearance, its accuracy relative to other CGM devices, plans for rollout and...


Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD
03/18/2024

W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham and the principal investigator of SURMOUNT-2, joins our hosts to provide perspective on several topics, including the FDA’s approval of tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more.

Key Timestamps

01:04 - Guest Introduction

03:45 - FDA Indication for Obesity

08:45 - SURMOUNT-2

17:40 - SURMOUNT-3 and -4

22:00 - Future of Incretin Therapies


SELECT, Semaglutide, & the Future of Incretin Therapies, with A. Michael Lincoff, MD
03/02/2024

In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit of semaglutide 2.4 mg beyond weight reduction, FLOW trials implications, and the future of incretin therapies.

Chapters:
00:35 - Guest Introduction
01:10 - SELECT Results Overview
04:25 - Next Steps for Research
07:15 - Mechanism of Action for CV Benefit
09:00 - FLOW Trial Implications
11:25 - Impact on Access
15:00 - Future of Incretin Therapies
21:45 - Predicting the Next 5-10 Years for Semaglutide


Understanding MARD, Comparing Popular CGM Sensors
02/29/2024

In this episode, the hosts breakdown a pair of recent publications related to better understanding the strengths and limitations of MARD as well as a study comparing the Dexcom G7 and FreeStyle Libre 3 sensors.

Video version: https://www.hcplive.com/view/diabetes-dialogue-understanding-mard-comparing-popular-cgm-sensors

Key Highlights:
00:35 - The Myth of MARD
04:10 - Considerations When Interpreting MARD
10:15 - FreeStyle Libre 3 vs. Dexcom G7